Evidence map›Paper›PMID 25605963›Full record

ArticleRNA (New York, N.Y.)2015

Using droplet-based microfluidics to improve the catalytic properties of RNA under multiple-turnover conditions.

Michael Ryckelynck, Stéphanie Baudrey, Christian Rick, Annick Marin, Faith Coldren, Eric Westhof, Andrew D Griffiths

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cross-chiral exponential amplification of an RNA enzyme.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Structure-based insights into fluorogenic RNA aptamers.Acta biochimica et biophysica Sinica · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Cell-Free Production Systems in Droplet Microfluidics.Advances in biochemical engineering/biotechnology · 2023
    Review
  10. Aptamers as Functional Modules for DNA Nanostructures.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  11. Pushing the Limits of Nucleic Acid Function.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Michael RyckelynckArchitecture et Réactivité de l'ARN, CNRS UPR 9002, Université de Strasbourg, 67084 Strasbourg, France Institut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 67083 Strasbourg, France andrew.griffiths@espci.fr m.ryckelynck@unistra.fr.
Stéphanie BaudreyArchitecture et Réactivité de l'ARN, CNRS UPR 9002, Université de Strasbourg, 67084 Strasbourg, France.
Christian RickArchitecture et Réactivité de l'ARN, CNRS UPR 9002, Université de Strasbourg, 67084 Strasbourg, France Institut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 67083 Strasbourg, France.
Annick MarinInstitut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 67083 Strasbourg, France.
Faith ColdrenInstitut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 67083 Strasbourg, France.
Eric WesthofArchitecture et Réactivité de l'ARN, CNRS UPR 9002, Université de Strasbourg, 67084 Strasbourg, France.
Andrew D GriffithsInstitut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 67083 Strasbourg, France Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI ParisTech), CNRS UMR 8231, 75231 Paris, France andrew.griffiths@espci.fr m.ryckelynck@unistra.fr.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vitro evolution methodologies are powerful approaches to identify RNA with new functionalities. While Systematic Evolution of Ligands by Exponential enrichment (SELEX) is an efficient approach to generate new RNA aptamers, it is less suited for the isolation of efficient ribozymes as it does not select directly for the catalysis. In vitro compartmentalization (IVC) in aqueous droplets in emulsions allows catalytic RNAs to be selected under multiple-turnover conditions but suffers severe limitations that can be overcome using the droplet-based microfluidics workflow described in this paper. Using microfluidics, millions of genes in a library can be individually compartmentalized in highly monodisperse aqueous droplets and serial operations performed on them. This allows the different steps of the evolution process (gene amplification, transcription, and phenotypic assay) to be uncoupled, making the method highly flexible, applicable to the selection and evolution of a variety of RNAs, and easily adaptable for evolution of DNA or proteins. To demonstrate the method, we performed cycles of random mutagenesis and selection to evolve the X-motif, a ribozyme which, like many ribozymes selected using SELEX, has limited multiple-turnover activity. This led to the selection of variants, likely to be the optimal ribozymes that can be generated using point mutagenesis alone, with a turnover number under multiple-turnover conditions, k(ss) cat, ∼ 28-fold higher than the original X-motif, primarily due to an increase in the rate of product release, the rate-limiting step in the multiple-turnover reaction.

Indexed as

Directed Molecular EvolutionAptamers, NucleotideDNAMicrofluidicsRNA, CatalyticSELEX Aptamer TechniqueAptamers, NucleotideDNARNA, Catalyticdroplet-based microfluidicshigh-throughput screeningin vitro evolutionribozymesRNA

Identifiers

PMID25605963
PMCPMC4338340
OpenAlexW2130573623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.